Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 158 participants.
Also called NCT01932970
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 158 participants
- Sponsor
- Registry
-
NCT01932970 -
2013-000964-28
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01932970. Allocation not applicable; no masking; primary purpose treatment. Start 2013-08-12 (actual); primary completion 2014-01-14 (actual). Results posted on 2017-04-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide
- Condition
- Hyperparathyroidism, Secondary
- Intervention (Drug)
- Etelcalcetide
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct01932970- Content hash
2131138f2d9915d671c93a11fcffac6ef0c43522e2c21e8ebdf9395a18b4f2df